Surgery Branch
Head, Tumor Immunology Section
Branch Chief

National Cancer Institute
9000 Rockville Pike
Building 10, Room 3-3940
Bethesda, MD 20892

Phone: 301-496-4164
Fax: 301-402-1738
SAR@nih.gov

Dr. Rosenberg is Chief of Surgery at the National Cancer Institute (NCI) in Bethesda, Md., and a Professor of Surgery at the Uniformed Services University of the Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. Dr. Rosenberg received his B.A. and M.D. degrees from The Johns Hopkins University in Baltimore, Md., and his Ph.D. in biophysics from Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Mass., Dr. Rosenberg became Chief of Surgery at NCI, a position he has held to the present time.

Dr. Rosenberg's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with melanoma, kidney cancer, brain tumor, mesothelin expressing cancers, papillomavirus-associated cancers, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers NCI-12-C-0116, NCT01585428

A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma NCI-12-C-0114, NCT01585415

Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes NCI-12-C-0111, NCT01583686

A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII NCI-11-C-0266, NCT01454596

A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma NCI-11-C-0260, NCT01468818

A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma NCI-11-C-0170, NCT01369888

Phase II Study of Tumor Infiltrating Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion NCI-11-C-0163, NCT01369875

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI) NCI-11-C-0123, NCT01319565

Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes NCI-11-C-0013, NCT01218867

Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of CD8 Enriched Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12 NCI-11-C-0011, NCT01236573

A Phase II Study Using Short-Term Cultured, CD8+-enriched Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers NCI-10-C-0166, NCT01174121

Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia NCI-09-C-0082, NCT00924326

Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121, NCT00670748